Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Actuate Therapeutics, Inc. ACTU

Healthcare  —  Biotechnology
0.68 0.06 9.68% as of 25 Sep
Market cap
$15.9M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Actuate Therapeutics, Inc. (ACTU) Business Profile

Updated before January 2025

Company Overview

Actuate Therapeutics, Inc. (ACTU) is a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies for the treatment of cancer and other serious diseases. Founded in 2015, the company is headquartered in Fort Worth, Texas, with additional operations in Chicago, Illinois. Actuate Therapeutics was established with a mission to address unmet medical needs by leveraging cutting-edge science and technology to develop novel therapeutic solutions. The company is led by a team of experienced professionals, including CEO Daniel Schmitt and Chief Scientific Officer Dr. Frank Giles, who bring decades of expertise in oncology, drug development, and biotechnology.

Core Business Segments

Actuate Therapeutics focuses on the development of small-molecule therapeutics targeting key pathways involved in cancer and inflammatory diseases. The company’s primary product candidate is 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor. Below are the core business segments:

Oncology Therapeutics

  • 9-ING-41: Actuate’s lead product candidate, 9-ING-41, is a small-molecule inhibitor of GSK-3β. It is currently in Phase 2 clinical trials for the treatment of various cancers, including pancreatic cancer, glioblastoma, and triple-negative breast cancer. The drug has shown promise in preclinical and early clinical studies, demonstrating anti-tumor activity and potential synergy with existing chemotherapy agents.

Inflammatory Disease Therapeutics

  • Actuate is also exploring the potential of 9-ING-41 in treating inflammatory and fibrotic diseases. The company is conducting preclinical studies to evaluate the drug’s efficacy in conditions such as pulmonary fibrosis and other chronic inflammatory disorders.

Combination Therapies

  • Actuate is actively investigating the use of 9-ING-41 in combination with other therapeutic agents to enhance efficacy and overcome resistance mechanisms in cancer treatment. These combination strategies aim to provide more comprehensive treatment options for patients.

Business Model

Actuate Therapeutics operates as a research-driven biopharmaceutical company with a focus on clinical development and strategic partnerships. The company’s business model revolves around the following key components:

  1. Research and Development (R&D): Actuate invests heavily in R&D to advance its pipeline of innovative therapies. The company collaborates with academic institutions, research organizations, and industry partners to accelerate drug discovery and development.
  2. Clinical Trials: Actuate conducts rigorous clinical trials to evaluate the safety and efficacy of its product candidates. The company’s clinical programs are designed to address high unmet medical needs and target specific patient populations.
  3. Partnerships and Licensing: Actuate seeks strategic partnerships with pharmaceutical companies to co-develop and commercialize its therapies. These collaborations provide access to additional resources and expertise while sharing the risks and rewards of drug development.
  4. Revenue Generation: Although Actuate is currently in the clinical-stage and does not yet generate revenue from product sales, the company plans to monetize its therapies through licensing agreements, milestone payments, and royalties once its products receive regulatory approval.

Strategic Direction

Actuate Therapeutics is committed to advancing its pipeline of innovative therapies and expanding its impact in the biopharmaceutical industry. The company’s strategic priorities include:

  1. Advancing Clinical Programs: Actuate aims to complete Phase 2 clinical trials for 9-ING-41 and initiate Phase 3 trials in the near future. The company is also exploring additional indications for its lead candidate.
  2. Expanding Pipeline: Actuate is actively pursuing the discovery and development of new small-molecule therapeutics targeting critical pathways in cancer and inflammatory diseases.
  3. Global Expansion: The company plans to expand its presence in international markets by establishing partnerships with global pharmaceutical companies and conducting clinical trials in diverse patient populations.
  4. Sustainability Goals: Actuate is committed to sustainable practices in its operations and aims to minimize its environmental footprint through efficient resource utilization and waste reduction.

Competitive Landscape

Actuate Therapeutics operates in a highly competitive biopharmaceutical industry, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Pharmaceutical Giants: Companies like Pfizer, Merck, and Bristol-Myers Squibb have extensive oncology portfolios and significant resources for drug development.
  • Biotech Firms: Emerging companies such as Blueprint Medicines, Mirati Therapeutics, and Arcus Biosciences are also developing innovative cancer therapies targeting specific pathways.
  • Academic and Research Institutions: Universities and research organizations conducting cutting-edge cancer research may also compete for funding and intellectual property.

Risk Factors

Actuate Therapeutics faces several risks that could impact its operations and financial performance:

  1. Regulatory Risks: The company’s product candidates must undergo rigorous regulatory review before they can be marketed. Delays or failures in obtaining regulatory approval could hinder Actuate’s progress.
  2. Clinical Trial Risks: The success of Actuate’s clinical programs depends on the outcomes of its trials. Negative or inconclusive results could delay development timelines or lead to program discontinuation.
  3. Market Dependence: Actuate’s future revenue is heavily dependent on the success of 9-ING-41. Failure to commercialize this product could significantly impact the company’s financial prospects.
  4. Supply Chain Disruptions: The company relies on third-party manufacturers and suppliers for the production of its product candidates. Disruptions in the supply chain could affect clinical trial timelines and product availability.
  5. Competition: Intense competition in the biopharmaceutical industry could limit Actuate’s market share and pricing power.

Recent Developments

Actuate Therapeutics has made significant progress in advancing its clinical programs and expanding its pipeline. Recent developments include:

  • Clinical Trial Updates: The company announced positive interim results from its Phase 2 clinical trials of 9-ING-41, demonstrating promising efficacy and safety profiles in multiple cancer types.
  • New Indications: Actuate is exploring the potential of 9-ING-41 in additional indications, including rare cancers and inflammatory diseases.
  • Partnerships: The company has entered into strategic collaborations with leading academic institutions to accelerate drug discovery and development.
  • COVID-19 Impact: Actuate has implemented measures to mitigate the impact of the COVID-19 pandemic on its operations, including remote work policies and adjustments to clinical trial protocols.

Investment Considerations

Investors considering Actuate Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Actuate’s focus on novel therapeutic targets positions it as a leader in the development of next-generation cancer therapies.
  • Experienced Leadership: The company’s management team has a proven track record in drug development and commercialization.
  • Strategic Partnerships: Collaborations with academic institutions and industry partners enhance Actuate’s capabilities and resources.

Risks

  • Early-Stage Company: As a clinical-stage company, Actuate does not yet generate revenue from product sales and remains dependent on external funding.
  • Regulatory and Clinical Risks: The success of Actuate’s programs depends on the outcomes of clinical trials and regulatory approvals.
  • Market Competition: Intense competition in the oncology space could limit Actuate’s market opportunities.

Conclusion

Actuate Therapeutics, Inc. is a promising biopharmaceutical company with a strong focus on developing innovative therapies for cancer and inflammatory diseases. With its lead product candidate, 9-ING-41, showing significant potential in clinical trials, Actuate is well-positioned to address unmet medical needs and create value for patients and investors. While the company faces risks inherent to the biopharmaceutical industry, its experienced leadership, strategic partnerships, and commitment to innovation provide a solid foundation for future growth.